Search results
Showing 76 to 90 of 116 results for rheumatoid arthritis
Tofacitinib for moderately to severely active ulcerative colitis (TA547)
Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults.
Discontinued Reference number: GID-TAG402
Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.
This guideline covers improving oral health by developing and implementing a strategy that meets the needs of people in the local community. It aims to promote and protect people’s oral health by improving their diet and oral hygiene, and by encouraging them to visit the dentist regularly.
Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers
This guidance has been updated and replaced by NICE guideline NG100.
Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]
Discontinued Reference number: GID-TA11108
Tocilizumab for the treatment of rheumatoid arthritis (TA198)
This guidance has been updated and replaced by NICE technology appraisal guidance 247.
This guidance has been updated and replaced by NICE technology appraisal guidance 195.
This appraisal has been updated and replaced by NICE technology appraisal guidance 195.
Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)
Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making
Filgotinib for treating moderately to severely active Crohn's disease [ID6236]
Discontinued Reference number: GID-TA11244
Find out more about NICE technology appraisals advisory committee D members
This quality standard covers prevention, behavioural management, assessment, and treatment of overweight, obesity and central adiposity in children and young people aged over 2 years, and adults. This includes those with established comorbidities, and those with risk factors for other medical conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS212Show all sections
Sections for QS212
- Quality statements
- Quality statement 1: Recording BMI and waist-to-height ratio in adults
- Quality statement 2: Recording BMI in children and young people aged over 2 years
- Quality statement 3: Access to services for people with a learning disability
- Quality statement 4: Maintaining details of local and national overweight and obesity management interventions and services
- Quality statement 5: Providing information about local and national weight management interventions and services
- Quality statement 6: Wraparound care alongside medicines for weight management
- Quality statement 7: Advice and support after stopping medicines for weight management or completing behavioural interventions
Certolizumab pegol for the treatment of rheumatoid arthritis (TA186)
This guidance has been updated and replaced by NICE technology appraisal guidance 375.